YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated August 15, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Enrollment target: 8 to 12
    • Start date changed from estimate of Jun 15, 2023 to Jun 28, 2023
    • Eligibility criteria shortened, about 18 words
    • Study site revised
    • Study description shortened, about 2 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
Trial Details
NCT Number NCT05913804
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: China Immunotech (Beijing) Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Relapsed or Refractory Multiple Myeloma
Related terms Multiple Myeloma, Recurrence
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov